PL3670522T3 - Krystaliczna postać chlorku rybozydu nikotynamidu - Google Patents

Krystaliczna postać chlorku rybozydu nikotynamidu

Info

Publication number
PL3670522T3
PL3670522T3 PL20153772T PL20153772T PL3670522T3 PL 3670522 T3 PL3670522 T3 PL 3670522T3 PL 20153772 T PL20153772 T PL 20153772T PL 20153772 T PL20153772 T PL 20153772T PL 3670522 T3 PL3670522 T3 PL 3670522T3
Authority
PL
Poland
Prior art keywords
crystalline form
nicotinamide riboside
riboside chloride
chloride
nicotinamide
Prior art date
Application number
PL20153772T
Other languages
English (en)
Inventor
Erik C. Carlson
Michael C. Standen
Westin M. Morrill
Original Assignee
W.R. Grace & Co. - Conn.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55163976&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3670522(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by W.R. Grace & Co. - Conn. filed Critical W.R. Grace & Co. - Conn.
Publication of PL3670522T3 publication Critical patent/PL3670522T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/048—Pyridine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL20153772T 2014-07-24 2015-07-24 Krystaliczna postać chlorku rybozydu nikotynamidu PL3670522T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462028702P 2014-07-24 2014-07-24
EP15825253.6A EP3174891B1 (en) 2014-07-24 2015-07-24 Crystalline form of nicotinamide riboside
PCT/US2015/041956 WO2016014927A2 (en) 2014-07-24 2015-07-24 Crystalline form of nicotinamide riboside
EP20153772.7A EP3670522B1 (en) 2014-07-24 2015-07-24 Crystalline form of nicotinamide riboside chloride

Publications (1)

Publication Number Publication Date
PL3670522T3 true PL3670522T3 (pl) 2022-02-21

Family

ID=55163976

Family Applications (2)

Application Number Title Priority Date Filing Date
PL20153772T PL3670522T3 (pl) 2014-07-24 2015-07-24 Krystaliczna postać chlorku rybozydu nikotynamidu
PL15825253T PL3174891T3 (pl) 2014-07-24 2015-07-24 Krystaliczna postać rybozydu nikotynamidu

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL15825253T PL3174891T3 (pl) 2014-07-24 2015-07-24 Krystaliczna postać rybozydu nikotynamidu

Country Status (7)

Country Link
US (2) US10323058B2 (pl)
EP (2) EP3174891B1 (pl)
CN (1) CN106715454B (pl)
CA (1) CA2956163C (pl)
ES (2) ES2776395T3 (pl)
PL (2) PL3670522T3 (pl)
WO (1) WO2016014927A2 (pl)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102629310B1 (ko) * 2015-03-09 2024-01-24 더블유.알. 그레이스 앤드 캄파니-콘. 니코틴아미드 리보사이드의 결정 형태
PL3331894T3 (pl) 2015-08-05 2021-08-23 Metro International Biotech, Llc Pochodne mononukleotydu nikotynamidowego i ich zastosowania
GB2542881B (en) 2015-10-02 2020-01-01 Carr Andrew Crystal forms of ß-nicotinamide mononucleotide
CA3017254C (en) 2016-03-16 2023-08-22 ChromaDex Inc. B-vitamin and amino acid conjugates of nicotinoyl ribosides and reduced nicotinoyl ribosides, derivatives thereof, and methods of preparation thereof
WO2017218580A1 (en) 2016-06-14 2017-12-21 Rejuvenation Therapeutics Corporation Synthetic methods for the preparation of nicotinamide riboside and related compounds
CA3045876A1 (en) 2016-11-11 2018-05-17 The Queen's University Of Belfast Scalable syntheses of nicotinoyl ribosides and reduced nic otinoyl ribosides, modified derivatives thereof, phosphorylated analogs thereof, adenylyl dinucleotide conjugates thereof, and novel crystalline forms thereof
US11071747B2 (en) 2016-11-29 2021-07-27 University Of Iowa Research Foundation Use of NAD precursors for breast enhancement
EP3554285A4 (en) 2016-11-29 2021-01-20 University of Iowa Research Foundation USE OF NAD PRECURSORS TO IMPROVE THE HEALTH OF MOTHER AND / OR OFFspring
WO2018236814A2 (en) 2017-06-19 2018-12-27 Gangadhara Ganapati NICOTINAMIDE RIBOSID DERIVATIVES AND USES THEREOF
WO2019126482A1 (en) * 2017-12-22 2019-06-27 Elysium Health, Inc. Crystalline forms of nicotinamide riboside chloride
US11180521B2 (en) 2018-01-30 2021-11-23 Metro International Biotech, Llc Nicotinamide riboside analogs, pharmaceutical compositions, and uses thereof
US11447514B2 (en) 2018-05-18 2022-09-20 Roche Diagnostics Operations, Inc. (Thio)nicotinamide ribofuranoside salts and compositions, methods of making, and uses thereof
CN108774278A (zh) * 2018-09-10 2018-11-09 张洪喜 一种制备尼克酰胺核苷盐的方法
BR112021011054A2 (pt) 2018-12-10 2021-08-31 ChromaDex Inc. Forma cristalina ii de ribosídeo de ácido nicotínico, e forma cristalina ii de triacetato ribosídeo de ácido nicotínico
WO2020131578A2 (en) 2018-12-17 2020-06-25 Mitopower Llc Nicotinyl riboside compounds and their uses
MX2021010043A (es) 2019-02-21 2022-07-19 Chromadex Inc Uso de nicotinamida ribósido, ácido nicotinico ribósido, compuestos de nicotinil ribósido reducido y derivados de compuestos de nicotinil ribósido en formulaciones.
US11939348B2 (en) 2019-03-22 2024-03-26 Metro International Biotech, Llc Compositions comprising a phosphorus derivative of nicotinamide riboside and methods for modulation of nicotinamide adenine dinucleotide
US10618927B1 (en) 2019-03-22 2020-04-14 Metro International Biotech, Llc Compositions and methods for modulation of nicotinamide adenine dinucleotide
CN114423771A (zh) 2019-07-19 2022-04-29 生物合成股份公司 制备烟酰胺呋喃核糖苷盐的方法、烟酰胺呋喃核糖苷盐本身及其用途
CN111808156A (zh) * 2020-07-15 2020-10-23 许昌远志生物科技有限公司 一种β-烟酰胺核糖氯化物的晶型1A、晶型1B及其制备方法
US20230271995A1 (en) * 2020-09-15 2023-08-31 Societe Des Produits Nestle S.A. Methods for producing dihydronicotinamide riboside from nicotinamide riboside chloride
CA3219033A1 (en) 2021-05-27 2022-12-01 Metro International Biotech, Llc Crystalline solids of nicotinic acid mononucleotide and esters thereof and methods of making and use

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1190080A (en) 1966-08-08 1970-04-29 Kyowa Hakko Kogyo Company Ltd Process for producing Nicotinamide Adenine Dinucleotide
US3728111A (en) 1971-09-21 1973-04-17 Asea Ab Method of manufacturing billets from powder
US6348589B1 (en) 1997-02-06 2002-02-19 Inspire Pharmaceuticals, Inc. Certain dinucleotides and their use as modulators of mucociliary clearance and ciliary beat frequency
GB9712370D0 (en) 1997-06-14 1997-08-13 Aepact Ltd Therapeutic systems
KR20030081343A (ko) 2000-12-15 2003-10-17 파마셋, 리미티드 플라비비리다에 감염 치료용 항바이러스제
US7179791B2 (en) 2001-01-11 2007-02-20 Duke University Inhibiting GS-FDH to modulate NO bioactivity
US7977049B2 (en) 2002-08-09 2011-07-12 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
US20050020587A1 (en) 2003-07-25 2005-01-27 Pfizer Inc Nicotinamide derivatives useful as PDE4 inhibitors
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
JP2007521835A (ja) 2004-02-10 2007-08-09 トラスティーズ・オブ・ダートマウス・カレッジ ニコチンアミドリボシドキナーゼ組成物およびそれらの使用方法
US8114626B2 (en) 2004-02-10 2012-02-14 Trustees Of Dartmouth College Yeast strain and method for using the same to produce nicotinamide riboside
AU2005257883A1 (en) 2004-06-04 2006-01-05 Washington University Methods and compositions for treating neuropathies
CN101163693B (zh) 2005-02-18 2013-03-06 阿斯利康(瑞典)有限公司 抗菌哌啶衍生物
CA2610854A1 (en) 2005-03-30 2006-10-05 Sirtris Pharmaceuticals, Inc. Nicotinamide riboside and analogues thereof
US20070149466A1 (en) 2005-07-07 2007-06-28 Michael Milburn Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
EP1957086B1 (en) * 2005-11-18 2018-05-02 Cornell Research Foundation, Inc. Nicotinoyl riboside compositions and methods of use
WO2007102861A2 (en) 2005-12-02 2007-09-13 Sirtris Pharmaceuticals, Inc. Modulators of cdc2-like kinases (clks) and methods of use thereof
WO2007136744A1 (en) 2006-05-19 2007-11-29 The Johns Hopkins University Crystal structure of a substrate complex of nampt/pbef/visfatin
JP2010513458A (ja) 2006-12-19 2010-04-30 ファイザー・プロダクツ・インク Ｈ−ｐｇｄｓの阻害剤としてのニコチンアミド誘導体、およびプロスタグランジンｄ２の仲介による疾患を治療するためのその使用
CA2676609A1 (en) 2007-01-26 2008-07-31 Washington University Methods and compositions for treating neuropathies
WO2009153721A1 (en) 2008-06-18 2009-12-23 Pfizer Limited Nicotinamide derivatives
EP2313074A4 (en) 2008-06-30 2015-04-15 Elc Man Llc TOPICAL COMPOSITIONS CONTAINING ISONICOTINAMIDE
KR20110026019A (ko) 2008-08-06 2011-03-14 시코르, 인크. 아자시티딘 중간체의 제조 방법
WO2011005289A2 (en) 2009-06-23 2011-01-13 President And Fellows Of Harvard College Methods and kits for measuring enzyme activity
UA108856C2 (uk) 2009-07-24 2015-06-25 Пунікалін (punicalin) та пунікалагін (punicalagin) для захисту здоров'я головного мозку при нейродегенеративних розладах
US8507251B2 (en) 2009-09-28 2013-08-13 Robert J. Greenstein Medium and method for culturing Mycobacterium avium subspecies paratuberculosis
US9603862B2 (en) 2009-12-14 2017-03-28 Cornell University Activation and activators of SIRT5
EP2464249B1 (de) 2010-03-29 2013-03-13 Johannes Huber Konzentrationssteigerndes getränk
JP5663576B2 (ja) 2010-07-06 2015-02-04 秀則 上西 神経突起伸長剤
US20140065099A1 (en) 2011-02-15 2014-03-06 Ecole Polytechnique Federale De Lausanne (Epfl) Methods of Treating Mitochondrial Dysfunction
US20120107888A1 (en) 2011-02-17 2012-05-03 Qteros, Inc. Modulation of fermentation products through vitamin supplementation
US20120328526A1 (en) 2011-06-27 2012-12-27 University Of Maryland, Baltimore Modulation of Nad+ Activity in Neuropathophysiological Conditions and Uses Thereof
CA2840516A1 (en) 2011-06-29 2013-01-03 President And Fellows Of Harvard College Small molecule cd38 inhibitors and methods of using same
EA201490050A1 (ru) 2011-06-29 2014-07-30 Зе Дженерэл Хоспитэл Корпорейшн Композиции и способы повышения биоэнергетического состояния женских зародышевых клеток
CN104780782A (zh) 2012-07-09 2015-07-15 诺格罗有限责任公司 使用膳食补充剂预防酒精反应
US20140256760A1 (en) 2012-07-09 2014-09-11 Noglo Llc Reduction or prevention of alcohol reaction with dietary supplements
JP6289460B2 (ja) 2012-07-16 2018-03-07 コーネル ユニヴァーシティー 難聴を治療するためのニコチンアミドリボシド
WO2014059029A1 (en) 2012-10-09 2014-04-17 President And Fellows Of Harvard College Treatment of age-related and mitochondrial diseases by inhibition of hif-1 alpha function
WO2014111906A1 (en) 2013-01-21 2014-07-24 Ecole Polytechnique Federale De Lausanne (Epfl) Bioluminescence imaging of small biomolecules
AU2014236687A1 (en) 2013-03-15 2015-09-10 Nusirt Sciences, Inc. Leucine and nicotinic acid reduces lipid levels
GB201313465D0 (en) * 2013-07-29 2013-09-11 Queens University Of The Belfast Methods of preparing nicotinamide riboside and derivatives thereof
US9597271B2 (en) 2013-10-24 2017-03-21 The Procter & Gamble Company Cosmetic compositions and methods
KR20150050406A (ko) 2013-10-29 2015-05-08 한림대학교 산학협력단 니코틴아마이드 라이보사이드를 유효성분으로 포함하는 패혈증 치료 또는 예방용 약제학적 조성물
US10688118B2 (en) 2013-10-30 2020-06-23 ChromaDex Inc. Nicotinamide riboside compositions for topical use in treating skin conditions
CA2929666C (en) 2013-11-12 2023-08-01 Ortho-Nutra, Llc Theacrine-based supplement and method of use thereof
WO2015099842A1 (en) 2013-12-23 2015-07-02 Abbott Laboratories Hot beverage fortifier
JP2017511304A (ja) 2014-03-13 2017-04-20 ソーク インスティチュート フォー バイオロジカル スタディーズ フェキサラミン類似体ならびに作製方法および使用方法
EP3116878A4 (en) 2014-03-13 2018-02-14 Salk Institute for Biological Studies Fxr agonists and methods for making and using
US20150297508A1 (en) 2014-04-21 2015-10-22 William Andriette Topical Formulation to Enhance Genital Sensation and Function
EP3149016A1 (en) * 2014-06-02 2017-04-05 Glaxosmithkline Intellectual Property (No. 2) Limited Preparation and use of crystalline beta-d-nicotinamide riboside
EP3152220A1 (en) 2014-06-06 2017-04-12 Glaxosmithkline Intellectual Property (No. 2) Limited Nicotinamide riboside analogs and pharmaceutical compositions and uses thereof
US20170202822A1 (en) 2014-07-17 2017-07-20 The Scripps Research Institute Methods and compositions for enhancing cancer therapy
KR102629310B1 (ko) * 2015-03-09 2024-01-24 더블유.알. 그레이스 앤드 캄파니-콘. 니코틴아미드 리보사이드의 결정 형태

Also Published As

Publication number Publication date
PL3174891T3 (pl) 2020-08-10
CA2956163A1 (en) 2016-01-28
EP3174891B1 (en) 2020-01-29
EP3174891A2 (en) 2017-06-07
WO2016014927A3 (en) 2016-09-15
US10233207B2 (en) 2019-03-19
CA2956163C (en) 2023-01-10
EP3670522A1 (en) 2020-06-24
EP3174891A4 (en) 2018-05-30
US20180086783A1 (en) 2018-03-29
CN106715454A (zh) 2017-05-24
EP3670522B1 (en) 2022-01-19
ES2776395T3 (es) 2020-07-30
CN106715454B (zh) 2020-06-16
WO2016014927A2 (en) 2016-01-28
ES2908332T3 (es) 2022-04-28
US10323058B2 (en) 2019-06-18
US20170210774A1 (en) 2017-07-27

Similar Documents

Publication Publication Date Title
PL3670522T3 (pl) Krystaliczna postać chlorku rybozydu nikotynamidu
ZA201705776B (en) Crystalline form of nicotinamide riboside
GB2542881B (en) Crystal forms of ß-nicotinamide mononucleotide
ZA201608843B (en) Chloride salt of tat-nr2b9c
IL248529B (en) Palladianolide pyridine compounds and methods of use
SI3380554T1 (sl) Kristalne oblike per-kloro-gama-ciklodekstrinov
PL3113773T3 (pl) Krystaliczne postaci grapiprantu
SG10202101979TA (en) Crystalline forms of c21h22ci2n4o2
IL251863A0 (en) Crystalline forms of ferric-maltol
SI3529236T1 (sl) Kristalinične oblike eravaciklina
EP3207034A4 (en) Anhydrous crystalline form of s-equol
IL253479A0 (en) Crystalline forms of efinconazole
GB2556529B (en) Methods of drilling
HUP1500506A2 (en) Salts of palbociclib